A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Trial details
- Registry ID
- NCT06981078
- Drugs studied
- Verekitug
TrialRedline tracks 4 clinical trials sponsored by Upstream Bio Inc.: 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDNCT06981078 | Verekitug | Active not recruiting | 2027-10Estimated |
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)NCT06966479 | Verekitug | Active not recruiting | 2027-09Estimated |
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)NCT06196879 | Verekitug (UPB-101) | Completed | 2025-12-16Actual |
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal PolypsNCT06164704 | Verekitug (UPB-101) | Completed | 2025-07-07Actual |
Names as written in the registry records.
NCT06981078 · Upstream Bio Inc.
Before: Apr 2028. After: Oct 2027.
NCT06981078 · Upstream Bio Inc.
Before: Recruiting. After: Active not recruiting.
NCT06966479 · Upstream Bio Inc.
Before: Estimated. After: Actual.
Before: 436 participants (planned). After: 396 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT06196879 · Upstream Bio Inc.
Before: Active not recruiting. After: Completed.
NCT06196879 · Upstream Bio Inc.
Before: Estimated. After: Actual.
Before: 19 Feb 2026. After: 16 Dec 2025.